COVID Vaccines and the Return to Life: The Latest on Kids and Teens aspeninstitute.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from aspeninstitute.org Daily Mail and Mail on Sunday newspapers.
Opinion: Vaccine hesitancy goes back 200 years. We need global techniques here in the U.S.
Michael Nyenhuis
FacebookTwitterEmail
Shots of the Pfizer coronavirus vaccine seen on May 12.Ron Harris/Associated Press
When it comes to vaccinations, the Bay Area is outpacing other counties in California and across the country. Yet vaccine hesitancy remains a barrier to achieving herd immunity here and elsewhere.
The debate around vaccine misinformation and the ease with which it spreads on social media is dominating the news right now. But vaccine hesitancy is a centuries-old problem that transcends technology, borders and political affiliations.
It has existed since the first vaccine was invented for smallpox in 1796. As that vaccine was introduced widely in England, some religious clerics and medical professionals were skeptical that it was safe; some even charged that the vaccine would “leave children with distinctly bovine features.” This misinformation spread faster than
“I don’t see a lot going well for them at this point,” said one analyst.
A participant in Novavax’s Phase 3 trials at Howard University in Washington earlier this year.Credit.Kenny Holston for The New York Times
May 11, 2021
Novavax, one of the first players in the race to vaccinate the world against Covid, delivered disheartening news on Monday, saying that its highly protective vaccine would not be authorized in the United States or Britain until at least July, and that it would not reach peak production until the end of the year.
The delays, announced during an earnings call with investors, are the latest setback for the little-known Maryland company, which was granted up to $1.6 billion from the U.S. federal government last year and whose product has shown robust results in clinical trials. Despite these wins, the company has struggled to demonstrate that it can deliver on its promise to supply the world with 2 billion doses this year. Novavax has never brought a vacc
Sat, 08 May 2021 02:00 UTC
A new Vaccination Demand Observatory is using surveillance, bots, and behavior change mass marketing schemes to press reluctant people into getting the shots
The U.S. is awash in a surplus of coronavirus vaccines as there has been a sudden in drop in demand for them; most Americans who want the shots have had them. Now an army of Big Biotech s agencies set up to address vaccine hesitancy are turning up their mass marketing to create demand using surveillance, rapid data analysis, media control, and host of behavior control strategies they ve outlined in their playbooks.
Demand plummets